From: Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer
Factors | Total (%) | TROP2 expression | p-value | |
---|---|---|---|---|
Cohort 1 | Â | Low (%) | High (%) | Â |
 Age (yr) |  |  |  | .107 |
   < 50 | 426 (59.6) | 176 (56.2) | 250 (62.2) |  |
   ≥ 50 | 289 (40.4) | 137 (43.8) | 152 (37.8) |  |
 Nuclear grade |  |  |  | .199 |
  1–2 | 184 (25.7) | 88 (28.1) | 96 (23.9) |  |
  3 | 531 (74.3) | 225 (71.9) | 306 (76.1) |  |
 Histologic grade |  |  |  | .477 |
  1–2 | 178 (24.9) | 82 (26.2) | 96 (23.9) |  |
  3 | 537 (75.1) | 231 (73.8) | 306 (76.1) |  |
 Histologic type |  |  |  | .825 |
  IBC-NST | 596 (83.4) | 262 (83.7) | 34 (83.1) |  |
  Non-IBC-NST | 119 (16.6) | 51 (16.3) | 68 (16.9) |  |
 pT |  |  |  | .578 |
  1–2 | 689 (96.4) | 303 (96.8) | 386 (96.0) |  |
  3–4 | 26 (3.6) | 10 (3.2) | 16 (4.0) |  |
 LN status |  |  |  | .945 |
  Negative | 467 (65.3) | 204 (65.2) | 263 (65.4) |  |
  Positive | 248 (34.7) | 109 (34.8) | 139 (34.6) |  |
 LVI |  |  |  | .989 |
  Negative | 537 (75.1) | 235 (75.1) | 302 (75.1) |  |
  Positive | 178 (24.9) | 78 (24.9) | 100 (24.9) |  |
 Stage |  |  |  | .936 |
  1 | 241 (33.7) | 105 (33.5) | 136 (33.8) |  |
  2–3 | 474 (66.3) | 208 (66.5) | 266 (66.2) |  |
 TILs (%) |  |  |  | .638 |
   < 10 | 169 (23.6) | 79 (25.2) | 90 (22.4) |  |
  10–59 | 320 (44.8) | 139 (44.4) | 181 (45.0) |  |
  60–100 | 226 (31.6) | 95 (30.4) | 131 (32.6) |  |
Cohort 2 | Â | Low (%) | High (%) | Â |
 Age (yr) |  |  |  | .439 |
   < 50 | 51 (77.3) | 15 (71.4) | 36 (80.0) |  |
   ≥ 50 | 15 (22.7) | 6 (28.6) | 9 (20.0) |  |
 Nuclear grade |  |  |  | .955 |
  2 | 16 (24.2) | 5 (23.8) | 11 (24.4) |  |
  3 | 50 (75.8) | 16 (76.2) | 34 (75.6) |  |
 Histologic grade |  |  |  | .979 |
  2 | 19 (28.8) | 6 (28.6) | 13 (28.9) |  |
  3 | 47 (71.2) | 15 (71.4) | 32 (71.1) |  |
 Histologic type |  |  |  | .683 |
  IBC-NST | 61 (92.4) | 19 (90.5) | 42 (93.3) |  |
  Non-IBC-NST | 5 (7.6) | 2 (9.5) | 3 (6.7) |  |
 ypT |  |  |  | .637 |
  1–2 | 57 (87.7) | 19 (90.5) | 38 (86.4) |  |
  3–4 | 8 (12.3) | 2 (9.5) | 6 (13.6) |  |
 LN status |  |  |  | .883 |
  Negative | 40 (60.6) | 13 (61.9) | 27 (60.0) |  |
  Positive | 26 (39.4) | 8 (38.1) | 26 (39.4) |  |
 LVI |  |  |  | .714 |
  Negative | 46 (69.7) | 14 (66.7) | 32 (71.1) |  |
  Positive | 20 (30.3) | 7 (33.3) | 13 (28.9) |  |
 Stage |  |  |  | .547 |
  1 | 31 (47.0) | 11 (52.4) | 20 (44.4) |  |
  2–3 | 35 (53.0) | 10 (47.6) | 25 (55.6) |  |
 TILs (%) |  |  |  | .811 |
   < 10 | 35 (53.0) | 10 (47.6) | 25 (55.6) |  |
  10–59 | 26 (39.4) | 9 (42.9) | 17 (37.8) |  |
  60–100 | 5 (7.6) | 2 (9.5) | 3 (6.7) |  |
 RCB class |  |  |  | .110 |
  1 | 2 (3.0) | 2 (9.5) | 0 |  |
  2 | 44 (66.7) | 13 (61.9) | 31 (68.9) |  |
  3 | 20 (30.3) | 6 (28.6) | 14 (31.1) |  |
 Miller-Payne grade |  |  |  | .660 |
  1 | 2 (3.0) | 1 (4.8) | 1 (2.2) |  |
  2 | 12 (18.2) | 3 (14.3) | 9 (20.0) |  |
  3 | 32 (48.5) | 10 (47.6) | 22 (48.9) |  |
  4 | 20 (30.3) | 7 (33.3) | 13 (28.9) |  |
Cohort 3 | Â | Low (%) | High (%) | Â |
 Age (yr) |  |  |  | .837 |
   < 50 | 18 (69.2) | 6 (66.7) | 12 (70.6) |  |
   ≥ 50 | 8 (30.8) | 3 (33.3) | 5 (29.4) |  |
 TILs (%) |  |  |  | .186 |
   < 2 | 7 (26.9) | 1 (11.1) | 6 (35.3) |  |
   ≥ 2 | 19 (73.1) | 8 (88.9) | 11 (64.7) |  |
 Site |  |  |  | .299 |
  Lung | 12 (46.2) | 5 (55.6) | 7 (41.2) |  |
  Brain | 11 (42.3) | 2 (22.2) | 9 (52.9) |  |
  Bone | 2 (7.7) | 1 (11.1) | 1 (5.9) |  |
  Soft tissue | 1 (3.8) | 1 (11.1) | 0 |  |